Concurrent radiochemotherapy (RCT) is the treatment of choice for patients with locally
advanced non–small-cell lung cancer (NSCLC). Two meta-analyses were inconclusive in an …

The efficacy and safety of carbon‐ion radiotherapy (CIRT) for locally advanced non‐small‐
cell lung cancer (LA‐NSCLC) remain unclear. We reported the clinical outcomes of CIRT for …

Concurrent chemotherapy/radiotherapy has been considered the standard treatment for
patients with a good performance status and inoperable stage III non-small-cell lung cancer …

For several decades, radiation therapy has been the mainstay of treatment for locally
advanced inoperable non–small cell lung cancer (NSCLC). Significant technologic …

Introduction Concurrent chemoradiotherapy (CRT) is standard therapy for locally advanced
NSCLC (LA-NSCLC) patients. This study was performed to examine thoracic radiotherapy …

INTRODUCTION: We report the long-term results of RTOG 9801, a randomized trial
investigating the ability of amifostine, a radioprotector, to reduce chemoradiation-induced …

For many years, thoracic radiotherapy had been regarded as the standard treatment for
patients with unresectable locally advanced non-small cell lung cancer. However, meta …

Locally advanced non-small cell lung cancer (LA-NSCLC) is a heterogeneous disease,
encompassing stage IIIA, for which surgery in combination with chemotherapy and/or …

Significant recent advances have occurred in the use of radiation therapy for locally
advanced non-small cell lung cancer (LA-NSCLC). In fact, the past few decades have seen …

For the treatment of locoregional advanced stage III non-small-cell lung cancer, when
chemotherapy is added sequentially to radiotherapy it acts systemically and is aimed at …